Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Majem M, Hernández-Hernández J, Hernando-Trancho F, Rodríguez de Dios N, Sotoca A, Trujillo-Reyes JC, Vollmer I, Delgado-Bolton R, Provencio M.

Clin Transl Oncol. 2019 Jun 6. doi: 10.1007/s12094-019-02134-7. [Epub ahead of print]

PMID:
31172444
2.

Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.

Sanmartín O, Beato C, Suh-Oh HJ, Aragón I, España A, Majem M, Segura S, Gúrpide A, Botella R, Grávalos C.

Actas Dermosifiliogr. 2019 Jul - Aug;110(6):448-459. doi: 10.1016/j.ad.2019.01.011. Epub 2019 Apr 19. English, Spanish.

PMID:
31010573
3.

Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients.

Sullivan I, Riera P, Andrés M, Altés A, Majem M, Blanco R, Capdevila L, Barba A, Barnadas A, Salazar J.

Angiogenesis. 2019 Aug;22(3):433-440. doi: 10.1007/s10456-019-09668-y. Epub 2019 Apr 11.

PMID:
30977010
4.

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.

Corral J, Majem M, Rodríguez-Abreu D, Carcereny E, Cortes ÁA, Llorente M, López Picazo JM, García Y, Domine M, López Criado MP.

Clin Transl Oncol. 2019 Sep;21(9):1270-1279. doi: 10.1007/s12094-019-02053-7. Epub 2019 Feb 15.

PMID:
30771085
5.

Differences in coping strategies among young adults and the elderly with cancer.

Hernández R, Calderon C, Carmona-Bayonas A, Rodríguez Capote A, Jara C, Padilla Álvarez A, Gómez-Camacho MLN, Beato C, Castelo B, Majem M, Muñoz MDM, Ivars A, Mangas-Izquierdo M, Rogado-Revuelta J, Jimenez-Fonseca P.

Psychogeriatrics. 2019 Feb 5. doi: 10.1111/psyg.12420. [Epub ahead of print]

PMID:
30723983
6.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB.

Ann Oncol. 2019 Feb 1;30(2):281-289. doi: 10.1093/annonc/mdy545.

PMID:
30657853
7.

SEOM clinical guidelines on nutrition in cancer patients (2018).

de Las Peñas R, Majem M, Perez-Altozano J, Virizuela JA, Cancer E, Diz P, Donnay O, Hurtado A, Jimenez-Fonseca P, Ocon MJ.

Clin Transl Oncol. 2019 Jan;21(1):87-93. doi: 10.1007/s12094-018-02009-3. Epub 2019 Jan 8.

8.

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.

J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.

PMID:
30472259
9.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).

Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M.

Clin Transl Oncol. 2019 Jan;21(1):3-17. doi: 10.1007/s12094-018-1978-1. Epub 2018 Nov 17.

10.

Risk of malnutrition and emotional distress as factors affecting health-related quality of life in patients with resected cancer.

Calderon C, Carmona-Bayonas A, Beato C, Ghanem I, Hernandez R, Majem M, Rosa Diaz A, Higuera O, Mut Lloret M, Jimenez-Fonseca P.

Clin Transl Oncol. 2019 May;21(5):687-691. doi: 10.1007/s12094-018-1954-9. Epub 2018 Oct 3.

PMID:
30284234
11.

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.

Grávalos C, Sanmartín O, Gúrpide A, España A, Majem M, Suh Oh HJ, Aragón I, Segura S, Beato C, Botella R.

Clin Transl Oncol. 2019 May;21(5):556-571. doi: 10.1007/s12094-018-1953-x. Epub 2018 Oct 3.

PMID:
30284232
12.

Lung cancer in Spanish women: The WORLD07 project.

Garrido P, Viñolas N, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E.

Eur J Cancer Care (Engl). 2019 Jan;28(1):e12941. doi: 10.1111/ecc.12941. Epub 2018 Oct 2.

PMID:
30277293
13.

BRAF inhibitors in metastatic non-small cell lung cancer.

Anguera G, Majem M.

J Thorac Dis. 2018 Feb;10(2):589-592. doi: 10.21037/jtd.2018.01.129. No abstract available.

14.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.

Gonzalez-Cao M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, Molina-Vila MÁ, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Muñoz E, Rodriguez-Abreu D, Perez E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R; Spanish Melanoma Group.

Melanoma Res. 2018 Jun;28(3):195-203. doi: 10.1097/CMR.0000000000000432.

PMID:
29481492
15.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.

Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M.

BMC Cancer. 2018 Jan 30;18(1):106. doi: 10.1186/s12885-018-4004-7.

16.

Small-cell lung cancer in the era of immunotherapy.

Majem M, Rudin CM.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S67-S70. doi: 10.21037/tlcr.2017.10.06. No abstract available.

17.

Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.

González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S21-S34. doi: 10.21037/tlcr.2017.10.03. Review.

18.

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.

Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, Jantús E, Remon-Massip J, Calabuig S, Aguiar D, Gil ML, Viñolas N, Santos-Rodríguez AK, Majem M, García-Peláez B, Villatoro S, Pérez-Rosado A, Monasterio JC, Ovalle E, Catalán MJ, Campos R, Morales-Espinosa D, Martínez-Bueno A, González-Cao M, González X, Moya-Horno I, Sosa AE, Karachaliou N, Rosell R, Molina-Vila MA.

Ann Oncol. 2017 Sep 1;28(9):2248-2255. doi: 10.1093/annonc/mdx288.

PMID:
28911086
19.

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C, Felip E.

Clin Transl Oncol. 2017 Dec;19(12):1537-1542. doi: 10.1007/s12094-017-1700-8. Epub 2017 Jun 28.

PMID:
28660482
20.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22.

PMID:
28625629

Supplemental Content

Loading ...
Support Center